<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695032</url>
  </required_header>
  <id_info>
    <org_study_id>07GENE03</org_study_id>
    <secondary_id>ICREGAUD-TOXIPLAT</secondary_id>
    <secondary_id>ICREGAUD-07-GENE-03</secondary_id>
    <secondary_id>EUDRACT-2007-004251-12</secondary_id>
    <secondary_id>INCA-RECF0479</secondary_id>
    <nct_id>NCT00695032</nct_id>
  </id_info>
  <brief_title>Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors</brief_title>
  <official_title>Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory&#xD;
      may help doctors learn more about changes that occur in DNA and identify biomarkers related&#xD;
      to cancer. It may also help doctors predict how patients will respond to treatment.&#xD;
&#xD;
      PURPOSE: This research study is evaluating kidney damage in patients receiving cisplatin and&#xD;
      ifosfamide for solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Identify and evaluate the early biomarkers of renal toxicity in patients with solid&#xD;
           tumors treated with cisplatin and ifosfamide.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate the modification of biomarker studies and blood concentrations of cisplatin.&#xD;
&#xD;
      OUTLINE: Patients receive standard chemotherapy comprising cisplatin and/or ifosfamide.&#xD;
&#xD;
      Blood and urine samples are collected on days 1 and 2 (or day 3 if receiving ifosfamide only)&#xD;
      during the first 3 courses. Samples are analyzed to determine plasma concentrations of&#xD;
      residual cisplatin and to obtain urinary-protein profiles to measure renal toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of different biomarkers</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity, specificity, and predictive value (positive and negative) of different markers</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chemotherapeutic Agent Toxicity</condition>
  <condition>Renal Toxicity</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of a solid tumor&#xD;
&#xD;
               -  Any location allowed&#xD;
&#xD;
               -  Metastatic disease allowed&#xD;
&#xD;
          -  Planned treatment comprising cisplatin and/or ifosfamide as standard chemotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Creatinine clearance â‰¥ 60 mL/min&#xD;
&#xD;
          -  Must be available for follow up&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Not under guardianship or in prison&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior drug-related nephrotoxicity&#xD;
&#xD;
          -  Acute, uncontrolled urinary infection or &gt; 48-hours&#xD;
&#xD;
          -  Pre-existing hemorrhagic cystitis&#xD;
&#xD;
          -  Weak bladder&#xD;
&#xD;
          -  Bilateral obstruction of urinary tract&#xD;
&#xD;
          -  Insufficient, severe bone marrow hypoplasia&#xD;
&#xD;
          -  Cardiorespiratory condition contraindicating hyperhydration&#xD;
&#xD;
          -  Hearing impairment&#xD;
&#xD;
          -  Hypersensitivity to cisplatin or products containing platinum&#xD;
&#xD;
          -  Major psychiatric condition (severe depression, psychosis, dementia)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior yellow fever vaccine, live attenuated vaccine, or phenytoin&#xD;
&#xD;
          -  No concurrent participation in another biomedical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Chevreau-Dalbianco, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>June 7, 2008</study_first_submitted>
  <study_first_submitted_qc>June 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal toxicity</keyword>
  <keyword>chemotherapeutic agent toxicity</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

